A Q&A session with the expert panel.
CancerNetwork®’s podcast hosted 2 experts to discuss the current state of biosimilar prescriptions and the need for change to improve the system overall.
COVID-19 created unexpected delays in oncologic treatment. This study sought to assess the volume of missed cancer-related services due to the pandemic.
Another installment of Clinical Quandaries is presented by Karen Férez-Blando, MD, and colleagues of a 45-year-old man with a diagnosis of intermediate-risk stage IV clear cell renal carcinoma who develops grade 2 hand-foot skin reaction on sunitinib therapy.
Javier Orozco-Mera, MD, FACS, MSc, and colleagues assess the signaling pathways and molecular mechanisms involved in the relapse of glioblastoma.
A Satellite Sessions program panel at the University of Texas MD Anderson Cancer Center discusses topics in multiple myeloma including the selection of triplet vs quadruplet treatment regimens and optimizing outcomes in the maintenance setting.
Mark T. Fleming, MD, spoke about how use of 18F-rhPSMA-7.3 for PET/CT scans in patients with recurrent prostate cancer bests conventional imaging.
Specialists in the field of multiple myeloma discuss bispecific antibodies, with a focus on the MajesTEC-1 study on teclistamab.
This special episode of “Oncology Peer Review On-The-Go” includes a discussion on relapsed/refractory follicular lymphoma with Javier Munoz, MD, MS, FACP.
Yancey Warren, Jr, MD, MAT, and colleagues investigate the use of integrative oncology services among young women with breast cancer.
Experts examine the case of a previously healthy woman, aged 32 years, presented to the oncology clinic with a 6-month history of left-breast tumor, mastalgia, and swollen axillary nodes.
P. Connor Johnson, MD, and Jeremy S. Abramson MD, MMSc, discuss available treatments for patients with Burkitt lymphoma and high-grade B-cell lymphoma.
This review article written by Danielle Gentile, PhD, et al, reviews the management of cancer-related fatigue in integrative oncology.
Biosignatures data from the PRINCE trial show sophisticated precision approaches may be necessary to optimize chemoimmunotherapy use in pancreatic ductal adenocarcinoma.
Best treatment approaches for patients with advanced NSCLC in the context of individualized therapy and an evolving therapeutic landscape.
Rohit Gupta, MD, et al review a case study of a 70-year-old man who presented with a head mass, and the final diagnosis was hepatocellular carcinoma.
Rahiya Rehman, MD, and co-investigators, research the importance of poor follow-up and care for survivors of childhood cancer.